阿奇霉素联合头孢噻肟钠治疗肺部感染的效果及对炎症因子水平的影响

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the effect of Azithromycin combined with Cefotaxime Sodium in treatment of pulmonary infection and its influence on level of inflammatory factor.Methods80 patients with pulmonary infection treated in Traditional Chinese Medicine Hospital of Anyi County from January 2015 to June 2016 were selected and they were divided into observation group(n=40)and control group(n=40)according to the random number table method.Observation group was treated with Azithromycin combined with Cefotaxime Sodium,while control group was treated with Cefotaxime Sodium.The curative effects,levels of inflammatory factors[C-reactive protein(CRP),tumor necrosis factor α(TNF-α),interleukin-6(IL-6)]and incidence rate of adverse reactions between two groups were compared.ResultsThe total effective rate of observation group was 95.00%,which was higher than 72.50%of control group(P<0.05).After treatment,the levels of TNF-α,IL-6,CRP of observation group were lower than those of control group(P<0.05).The incidence rate of adverse reactions of observation group was 7.50%,which was lower than 20.00%of control group,but the difference had no statistical difference(P>0.05).ConclusionAzithromycin combined with Cefotaxime Sodium in treatment of pulmonary infection have significant curative effect,and it can effectively adjust level of inflammatory factors and have less adverse reactions,which is worthy of clinical application.

Key words： Azithromycin Cefotaxime Sodium Pulmonary infection Effect Inflammatory factor

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YU Ke-jing

Cite this article:

YU Ke-jing. Effect of Azithromycin combined with Cefotaxime Sodium in treatment of pulmonary infection and its influence on level of inflammatory factor[J]. 中国当代医药, 2017, 24(21): 27-29.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I21/27

[1]	李英，徐峥，张海英，等.阿奇霉素相关房室传导阻滞[J].药物不良反应杂志，2014，16（3）：176-177.
[2]	周小林.比索洛尔治疗慢性阻塞性肺疾病合并肺部感染的疗效和安全性及其作用机制[J].职业与健康，2016，32（16）：2301-2304.
[3]	吴金锴.蒿芩麻杏石甘汤联合阿奇霉素治疗小儿支原体肺炎的疗效观察[J].中国中医药科技，2015，22（5）：576-577.
[4]	张桐，刘广义，曹永献，等.ICU重症脑疝患者肺部感染病原学特征及耐药谱分析[J].中华医院感染学杂志，2016，26（21）：4931-4934.
[5]	宁国强，项志雄，汪炜，等.心力衰竭合并肺部感染患者血清炎症因子水平变化及其与心肌功能的关系研究[J].中华医院感染学杂志，2016，26（24）：5599-5600，5644.
[6]	黄健，张志大，陈艳玲，等.替加环素联合头孢哌酮舒巴坦治疗多重耐药鲍曼不动杆菌肺部感染的临床效果[J].中国当代医药，2016，23（13）：145-147.
[7]	程劲光，刘建国，安丽青，等.头孢噻利治疗老年社区获得性肺炎疗效观察[J].中国药物与临床，2016，16（9）：1324-1326.
[8]	马花平.头孢哌酮钠/舒巴坦钠（舒普深）治疗老年人肺部感染的临床分析[J].中国当代医药，2016，23（24）：115-117.
[9]	陈德胜，肖秋林.阿奇霉素治疗小儿支原体肺炎的疗效观察[J].中国基层医药，2015，22（16）：2530-2532.
[10]	曹雪如.肺结核合并肺部感染患者的病原菌耐药性分析[J].国际呼吸杂志，2016，36（10）：735-738.
[11]	区雪婷，梁伟强，魏立平.肺部感染金黄色葡萄球菌的临床特点及药敏性分析[J].实用医学杂志，2015，31（17）：2898-2901.
[12]	何小霞.胸腺肽α1免疫调节对高龄老年肺部感染的应用价值分析[J].中国药业，2015，24（11）：6-7.
[13]	王海娟，吴涛，田桂珍，等.胸腺肽联合阿奇霉素治疗老年COPD继发肺部感染疗效及对肺功能和血气指标的影响[J].疑难病杂志，2016，15（3）：225-228.
[14]	王奇琍.清肺止痉活血法联合阿奇霉素治疗儿童支原体肺炎58例[J].中国中医药科技，2015，22（3）：336-337.
[15]	齐福权，杨华.利奈唑胺对甲氧西林耐药金黄色葡萄球菌肺部感染患者的临床疗效[J].中国生化药物杂志，2016，36（8）：65-67，70.